Krystal Biotech, Inc. (KRYS) Financial Statements

Executive TeamFinancials
Shareholders

Krystal Biotech financial statements at a glance

Krystal Biotech reported revenue of $389.13 million for fiscal year 2025 (ended December 31, 2025), up 33.9% from fiscal year 2024. Net income was $204.83 million, a net margin of 52.6%, and diluted earnings per share were $6.84.

At the end of fiscal year 2025 it had total assets of $1.33 billion, total liabilities of $114.23 million and shareholders' equity of $1.22 billion, with cash and short-term investments of $827.79 million and total debt of $9.34 million.

Its operations brought in $200.87 million of cash; capital spending was $11.95 million, leaving free cash flow of $188.91 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

KRYS logo

Krystal Biotech, Inc.

KRYSUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
389.13M
Prev Year: 290.51M
YoY: +33.9%
Operating Revenue
389.13M
Prev Year: 290.51M
YoY: +33.9%
Total Expenses
227.84M
Prev Year: 187.32M
YoY: +21.6%
Total Operating Income as Reported
161.29M
Prev Year: 65.69M
YoY: +145.5%
Diluted NI Available to Com Stockholders
204.83M
Prev Year: 89.16M
YoY: +129.7%
Cost of Revenue
23.05M
Prev Year: 20.06M
YoY: +14.9%
Gross Profit
366.08M
Prev Year: 270.45M
YoY: +35.4%
Operating Expense
204.79M
Prev Year: 167.26M
YoY: +22.4%
Selling General and Administrative
146.74M
Prev Year: 113.69M
YoY: +29.1%
Research and Development
58.05M
Prev Year: 53.57M
YoY: +8.3%
Operating Income
161.29M
Prev Year: 103.19M
YoY: +56.3%
Net Non Operating Interest Income Expense
28.18M
Prev Year: 29.66M
YoY: -5.0%
Non-operating Interest Income
28.18M
Prev Year: 29.66M
YoY: -5.0%
Pre-tax Income
189.47M
Prev Year: 95.36M
YoY: +98.7%
Other Income Expense
-
Prev Year: -37.50M
Provision for Income Taxes
-15.36M
Prev Year: 6.20M
YoY: -347.9%
Net Income Common Stockholders
204.83M
Prev Year: 89.16M
YoY: +129.7%
Net Income
204.83M
Prev Year: 89.16M
YoY: +129.7%
Net Income Including Non-Controlling Interests
204.83M
Prev Year: 89.16M
YoY: +129.7%
Net Income from Continuing Operations
204.83M
Prev Year: 89.16M
YoY: +129.7%
Basic EPS
7.08
Prev Year: 3.12
YoY: +126.9%
Diluted EPS
6.84
Prev Year: 3
YoY: +128.0%
Weighted Average Shares (basic)
28.94M
Prev Year: 28.59M
YoY: +1.2%
Weighted Average Shares (diluted)
29.95M
Prev Year: 29.74M
YoY: +0.7%
Net Income from Continuing and Discontinued Operation
204.83M
Prev Year: 89.16M
YoY: +129.7%
Normalized Income
204.83M
Prev Year: 124.22M
YoY: +64.9%
Interest Income
28.18M
Prev Year: 29.66M
YoY: -5.0%
Interest Expense
-
EBIT
161.29M
Prev Year: 103.19M
YoY: +56.3%
EBITDA
167.85M
Prev Year: 109.91M
YoY: +52.7%
Reconciled Cost of Revenue
23.05M
Prev Year: 20.06M
YoY: +14.9%
Reconciled Depreciation
6.55M
Prev Year: 6.71M
YoY: -2.4%
Net Income from Continuing Operation Net Minority Interest
204.83M
Prev Year: 89.16M
YoY: +129.7%
Net Interest Income
-
Prev Year: 29.66M
Normalized EBITDA
167.85M
Prev Year: 147.41M
YoY: +13.9%
Tax Rate for Calcs
0.21
Prev Year: 0
Values in USD

Krystal Biotech key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$389.1M$290.5M$50.7M––
Gross profit$366.1M$270.5M$47.6M––
Operating income$161.3M$103.2M-$97.2M-$120.2M-$68.3M
Net income$204.8M$89.2M$10.9M-$140.0M-$69.6M
Diluted EPS$6.84$3.00$0.39-$5.49-$3.13
Total assets$1.3B$1.1B$818.4M$558.5M$626.3M
Total liabilities$114.2M$109.5M$39.7M$36.2M$32.7M
Shareholders' equity$1.2B$946.4M$778.6M$522.2M$593.6M
Cash and short-term investments$827.8M$597.5M$532.2M$379.2M$438.1M
Total debt$9.3M$7.3M$8.1M$8.9M$8.0M
Operating cash flow$200.9M$123.4M-$88.8M-$100.6M-$47.9M
Capital spending$12.0M$4.2M$11.8M$53.0M$68.3M
Free cash flow$188.9M$119.2M-$100.6M-$153.5M-$116.3M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2016.

Questions and answers

What was Krystal Biotech's revenue in fiscal year 2025?

$389.13 million, up 33.9% from $290.52 million in fiscal year 2024.

How much profit does Krystal Biotech make?

Krystal Biotech reported net income of $204.83 million for fiscal year 2025 (52.6% of revenue); operating income was $161.30 million.

How much cash and debt does Krystal Biotech have?

At the end of fiscal year 2025: cash and short-term investments of $827.79 million and total debt of $9.34 million.

What is Krystal Biotech's free cash flow?

$188.91 million in fiscal year 2025 (operating cash flow of $200.87 million minus capital spending of $11.95 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube